Combining leading-edge biomedical technologies of tissue engineering, gene editing and immune cloaking to advance expertise in laboratory, clinical and therapeutic aspects of both solid organ (SOT) and stem cell (SCT) transplantation.
Building upon our highly successful Genome Canada Transplant Consortium linking over 20 leading universities and research-based commercial partners we are developing a unique, world-class, international program for personalized therapeutics for treatment of lethal human diseases.
Regenerative and Replacement Medicine
Leveraging the emerging aspects of leading-edge biomedical technologies of tissue engineering, gene editing and immune cloaking, we aim to generate a continuous supply of new stem cells, tissues and organs designed specifically to avoid rejection and failure. This will enable time-sensitive clinical transplantation in lethal human diseases without need for patient triage or refusal. These advances will be seamlessly integrated with research in structural biology, immune monitoring, advanced clinical therapeutics and innovative robotic surgical techniques to transform the fields of stem cell and solid organ transplantation and enable the induction of life-long tolerance while avoiding the lethal complications of viral infection and malignancy.
Immune Science Core
The Cluster's Immune Science Core team connects people from different departments who have not collaborated in the past (e.g., SCT and SOT) as well as other individuals who have an interest in immunology - clinicians, surgeons and technologists. Leading researchers at UBC in the Departments of Medicine, Surgery, Urology, Pathology and Pediatrics, with the Faculties of Science and Pharmaceutical Sciences, the Biomedical Research Centre, and the School of Biomedical Engineering, the School of Nursing and the School of Population and Public Health form the core team.